Xencor’s Promising Pipeline and Strong Financials Present Favorable Risk/Reward Opportunity Ahead of Key 2025 Data Readouts

In a report released yesterday, Eva Fortea Verdejo from Wells Fargo maintained a Buy rating on Xencor (XNCR – Research Report), with a price target of $33.00.

Eva Fortea Verdejo’s rating is based on the potential upside of Xencor’s stock, particularly with the anticipated readout of XmAb819 in the second half of 2025, which is expected to be a significant catalyst for the stock. The company is actively progressing with its pipeline, including the initiation of the XmAb942 Phase 2b study, which has shown promising results in earlier trials.
Additionally, Xencor’s financial position is strong, with substantial cash reserves to support ongoing research and development. Despite the stock’s significant decline year-to-date, Verdejo believes that the current valuation presents a favorable risk/reward opportunity, especially with the upcoming data readouts that could differentiate Xencor’s offerings in the competitive landscape.

According to TipRanks, Fortea Verdejo is a 2-star analyst with an average return of -1.7% and a 57.89% success rate. Fortea Verdejo covers the Healthcare sector, focusing on stocks such as Xencor, Arcus Biosciences, and Kiniksa Pharmaceuticals.